Wheezing Clinical Trial
Official title:
Development of Non-invasive Biomarkers to Direct Individualised Management of Preschool Wheeze
Preschool children (aged 1-5 years) account for 75% of all UK childhood wheezing hospitalisations. This has not changed over 20 years, meaning current treatments are not working and a new approach is needed. Currently, all preschool wheezers are treated with inhaled steroids. However, only about 25% of patients, with allergies, respond well to inhaled steroidsÍž for the other 75%, they are ineffective. This research group has found that some preschool wheezers may have other causes but there are no specific, non-invasive tests to match the right treatment to each child. The goal of this observational study is to test various bedside tests for this purpose in preschool children with wheeze, to see if they are feasible, accurate and acceptable in this age group. The research team would like to investigate the following aims: Aim 1 - To test the proposed panel of simple bedside tests below, to see how accurately they corelate with lower airway infection or inflammation. Aim 2 - To test the acceptability of these bedside tests are to parents and children, and if they reflect the child's symptoms, symptoms control and medication use. Aim 3- A small proof-of -concept study, to test if these simple bedside tests, can be used to determine treatment for each individual child. The panel of simple non-invasive tests that the research team are proposing are: 1. Skin prick tests to common allergies (house dust mite, cat, dog, grass, tree pollen, mixed moulds) 2. Finger prick blood test 3. Phlegm test for bacteria 4. Nose and throat swab for bacteria 5. Lung function test called forced oscillation technique (FOT)
Status | Recruiting |
Enrollment | 150 |
Est. completion date | August 31, 2026 |
Est. primary completion date | August 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 5 Years |
Eligibility | Inclusion Criteria: Aim 1, 2 and 3: - Children aged 1-5 years - More than 2 hospitalisations for acute wheeze in the last year or - At least 1 admission requiring high dependency unit or intravenous bronchodilator therapy in the last year. Aim 1 only: - children undergoing clinically indicated bronchoscopy, as determined by their existing medical team, as part of their standard management Exclusion Criteria: - Alternative respiratory diagnosis such as cystic fibrosis or bronchiectasis. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Brompton Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College London | Action Medical Research, Masonic Charitable Foundation, Royal Brompton & Harefield NHS Foundation Trust |
United Kingdom,
Robinson PFM, Fontanella S, Ananth S, Martin Alonso A, Cook J, Kaya-de Vries D, Polo Silveira L, Gregory L, Lloyd C, Fleming L, Bush A, Custovic A, Saglani S. Recurrent Severe Preschool Wheeze: From Prespecified Diagnostic Labels to Underlying Endotypes. Am J Respir Crit Care Med. 2021 Sep 1;204(5):523-535. doi: 10.1164/rccm.202009-3696OC. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Longitudinal study of skin prick tests as biomarkers of preschool wheeze | Specificity, sensitivity and longitudinal stability of skin prick tests to six common allergens (measured by size of wheal in response to skin prick, measured in mm) as a biomarker of allergen sensitisation. | 3 years | |
Primary | Longitudinal study of finger-prick point of care test for eosinophil count as a biomarker of preschool wheeze | Specificity, sensitivity and longitudinal stability of a finger-prick point of care test for eosinophil count (measured as cells per cubic mm) as a biomarker of eosinophilic inflammation. | 3 years | |
Primary | Longitudinal study of blood neutrophil phenotype as a biomarker of airway infection | Specificity, sensitivity and longitudinal stability of blood neutrophil phenotype (measured as mean fluorescence intensity for indicative phenotype markers) as a biomarker of airway infection. | 3 years | |
Primary | Longitudinal study of blood neutrophil chemotaxis as a biomarker of wheezing phenotype | Specificity, sensitivity and longitudinal stability of blood neutrophil chemotaxis (measured in micrometers per minute) as a biomarker of wheezing phenotype. | 3 years | |
Primary | Longitudinal study of oropharyngeal swab and induced sputum PCR as a biomarker of airway infection | Specificity, sensitivity and longitudinal stability of oropharyngeal swab and induced sputum PCR (measured by detectable presence or absence of DNA from Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis) as biomarkers of airway infection. Concordance between oropharyngeal swab and induced sputum PCR results from the same patient will also be assessed. | 3 years | |
Primary | Longitudinal study of lung function test (FOT) as a biomarker of airway reversibility | Specificity, sensitivity and longitudinal stability of lung function test (forced oscillation technique or FOT), measured by lung reactance and lung resistance (Rrs: respiratory system resistance; Xrs: respiratory system reactance; AX: area of reactance), as biomarkers of airway reversibility in wheezing patients. | 3 years | |
Secondary | Association between eosinophil counts and patient symptom control | Measurement of eosinophil counts (measured as cells per cubic mm) in relation to patient symptom control, using the Test for Respiratory and Asthma Control in Kids (TRACK), a caregiver-completed validated questionnaire for preschool-aged children (measured as mean symptom score). TRACK is a 5-item standardized questionnaire, with each item being scored from 0 to 20 points on a 5-point Likert-type scale. Total score ranging from 0 to 100. Higher scores indicate better respiratory and asthma control; a score of less than 80 points suggests that a child's breathing problems might not be controlled. | 3 years | |
Secondary | Patient acceptability of finger prick blood eosinophil count as a non-invasive biomarker in preschool wheeze | Determining the patient acceptability of finger prick blood eosinophil count as a non invasive biomarker test, using the Visual Analogue Scale (VAS) of pain intensity. The scale ranges from 0 to 10, with 0 being no pain or discomfort and 10 for worst pain possible. Higher scores indicate worse tolerability. | 3 years | |
Secondary | Patient acceptability of skin prick test as a non-invasive biomarker in preschool wheeze | Determining the patient acceptability of skin prick test as a non invasive biomarker test, using the Visual Analogue Scale (VAS) of pain intensity. The scale ranges from 0 to 10, with 0 being no pain or discomfort and 10 for worst pain possible. Higher scores indicate worse tolerability. | 3 years | |
Secondary | Patient acceptability of forced oscillation technique as a non-invasive biomarker to determine lung function and airway reversibility in preschool wheeze | Determining the patient acceptability of forced oscillation technique as a non invasive biomarker test, to determine lung function and airway reversibility in preschool children, using the Visual Analogue Scale (VAS) of pain intensity. The scale ranges from 0 to 10, with 0 being no pain or discomfort and 10 for worst pain possible. Higher scores indicate worse tolerability. | 3 years | |
Secondary | Patient acceptability of oropharyngeal swab and induced sputum PCR as a biomarker of airway infection in preschool wheeze | Determining the patient acceptability of oropharyngeal swab and induced sputum PCR as a biomarker of airway infection in preschool children, using the Visual Analogue Scale (VAS) of pain intensity. The scale ranges from 0 to 10, with 0 being no pain or discomfort and 10 for worst pain possible. Higher scores indicate worse tolerability. | 3 years | |
Secondary | Correlation between eosinophil counts and symptom burden of preschool wheeze to caregivers | Correlation between measurement of eosinophil counts (measured as cells per cubic mm) and assessment of symptom burden of preschool wheeze to caregivers using the validated Paediatric Asthma Caregivers Quality of Life Questionnaire (PACQLQ), measured by mean life quality score. This is a questionnaire that is self-administered by the caregiver, and assess symptom burden to caregivers, across two domains (activity limitations and emotional function). Each question is assessed using a 7-point Likert scales, with 1 indicating severe impairment and 7 indicating no impairment. Domains scores are calculated as the mean score across items in that domain. The overall score is the mean score across all items. The lowest score achievable is 1 and highest score achievable is 7, and higher scores indicate better quality of life. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04669288 -
AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department
|
Phase 3 | |
Withdrawn |
NCT04584034 -
Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial
|
Phase 4 | |
Terminated |
NCT02269761 -
Chest Ultrasound of ER Patients With Cough or SOB
|
||
Enrolling by invitation |
NCT00775697 -
Montelukast in Children With Wheezing
|
Phase 4 | |
Completed |
NCT00749528 -
Evaluation of Toxic Metals, Trace Elements and Total Antioxidant Activity in Children With Recurrent Wheezing
|
N/A | |
Recruiting |
NCT00494624 -
Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children
|
Phase 4 | |
Recruiting |
NCT04128592 -
Non-invasive Differential Diagnosis of Noisy Breathing Infants and Toddlers
|
N/A | |
Recruiting |
NCT06093152 -
Video Assisted Study of Salbutamol Response in Viral Wheezing
|
||
Completed |
NCT01452945 -
Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing
|
N/A | |
Withdrawn |
NCT00628303 -
A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants
|
Phase 3 | |
Completed |
NCT01028560 -
Allergy Immunotherapy for the Reduction of Asthma
|
Phase 1/Phase 2 | |
Completed |
NCT00626808 -
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
|
Phase 4 | |
Completed |
NCT00507676 -
Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing
|
N/A | |
Completed |
NCT03600428 -
Safety of LAIV4 in Children With Asthma
|
Phase 4 | |
Recruiting |
NCT06106646 -
Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up
|
||
Recruiting |
NCT05710081 -
Bacterial Lysate In Preventing Asthma
|
Phase 3 | |
Completed |
NCT04011709 -
A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy
|
Early Phase 1 | |
Active, not recruiting |
NCT03377192 -
Impedance Pneumography in Assessment of Asthma Control in Preschool Children
|
||
Completed |
NCT01142505 -
Wheeze and Intermittent Treatment
|
Phase 3 | |
Active, not recruiting |
NCT04942483 -
Using Specific Tests in Preschool Children With Wheeze to Help us Determine the Necessity of Inhaled Corticosteroid Therapy (Feasibility Study).
|